Published in Mol Cancer Ther on December 27, 2011
A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs. J Vet Intern Med (2015) 2.58
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem (2012) 1.17
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One (2014) 0.91
Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience (2013) 0.89
Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol (2014) 0.85
Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol (2013) 0.85
Cell-penetrating Peptide-mediated therapeutic molecule delivery into the central nervous system. Curr Neuropharmacol (2013) 0.85
Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Invest (2014) 0.83
Synthesis of double-clickable functionalised graphene oxide for biological applications. Chem Commun (Camb) (2015) 0.82
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol (2012) 0.81
Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release (2015) 0.79
Agile delivery of protein therapeutics to CNS. J Control Release (2014) 0.79
The Matricellular Receptor LRP1 Forms an Interface for Signaling and Endocytosis in Modulation of the Extracellular Tumor Environment. Front Pharmacol (2015) 0.78
Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review. World Neurosurg (2016) 0.78
Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci (2016) 0.78
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. Biomedicines (2016) 0.77
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv (2015) 0.76
Back to the tubule: microtubule dynamics in Parkinson's disease. Cell Mol Life Sci (2016) 0.75
Strategies to target drugs to gliomas and CNS metastases of solid tumors. J Neurol (2015) 0.75
Expression of Molecular Markers in Primary Sites and Metastatic Lymph Nodes of Lung Cancer Patients. Med Sci Monit (2017) 0.75
Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila. Dis Model Mech (2016) 0.75
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol (2006) 1.69
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res (2014) 1.35
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther (2003) 1.33
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res (2010) 1.30
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res (2012) 1.27
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res (2011) 1.26
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs (2008) 1.23
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol (2009) 1.21
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer (2010) 1.21
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol (2010) 1.15
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol (2009) 1.15
Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer (2003) 1.12
Reovirus-based therapy for cancer. Expert Opin Biol Ther (2009) 1.11
Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther (2012) 1.07
The Pim kinases: new targets for drug development. Curr Drug Targets (2011) 1.06
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res (2009) 1.04
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res (2010) 1.01
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res (2009) 1.00
Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs (2010) 0.98
Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol (2009) 0.98
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol (2011) 0.96
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol (2011) 0.95
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist (2014) 0.93
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res (2011) 0.91
Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer (2009) 0.91
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res (2007) 0.91
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol (2010) 0.90
Comparison of infrared versus contact thermometry for measuring skin temperature during exercise in the heat. Physiol Meas (2007) 0.90
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res (2011) 0.89
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res (2008) 0.89
Vitamin D status of early preterm infants and the effects of vitamin D intake during hospital stay. Arch Dis Child Fetal Neonatal Ed (2013) 0.88
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2013) 0.87
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer (2011) 0.87
Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environ Mol Mutagen (2005) 0.87
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res (2012) 0.87
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol (2012) 0.86
Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets (2009) 0.86
Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer (2013) 0.86
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res (2009) 0.85
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Curr Drug Targets (2011) 0.85
Interprofessional education: a nurse practitioner impacts family medicine residents' smoking cessation counselling experiences. J Interprof Care (2009) 0.85
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res (2010) 0.85
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs (2012) 0.84
Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer (2010) 0.83
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2008) 0.83
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol (2009) 0.83
Distinctive receptor binding properties of the surface glycoprotein of a natural feline leukemia virus isolate with unusual disease spectrum. Retrovirology (2011) 0.82
The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J (2003) 0.82
Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res (2013) 0.82
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs (2011) 0.82
Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res (2013) 0.81
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study. Clin Cancer Res (2009) 0.81
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.81
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol (2008) 0.81
RANK ligand: effects of inhibition. Curr Oncol Rep (2010) 0.80
Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.80
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs (2013) 0.80
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol (2014) 0.80
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.79
Heterogeneity in the effect of albumin and other resuscitation fluids on intracellular oxygen free radical production. J Trauma (2004) 0.79
The human milk project: a quality improvement initiative to increase human milk consumption in very low birth weight infants. Breastfeed Med (2012) 0.79
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs (2015) 0.79
Improving the institutional submission and approval process for clinical research protocols in oncology. J Clin Oncol (2007) 0.78
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Invest New Drugs (2014) 0.78
Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther (2011) 0.78
Evaluation of the Biotic Ligand Model relative to other site-specific criteria derivation methods for copper in surface waters with elevated hardness. Aquat Toxicol (2007) 0.78
Are we ready to move away from nature?: the rapamycin story. Target Oncol (2011) 0.78
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.76
Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy. Curr Oncol Rep (2015) 0.76
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother Pharmacol (2014) 0.75
Predicting success in regulatory approval from Phase I results. Cancer Chemother Pharmacol (2014) 0.75
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res (2013) 0.75
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs (2014) 0.75
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther (2015) 0.75
Level of acceptance of different models of maternity care. Can Nurse (2009) 0.75
Metabolism of patupilone in patients with advanced solid tumor malignancies. Invest New Drugs (2012) 0.75
Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. Leuk Lymphoma (2009) 0.75
What do you do to overcome your fears in midwifery and/or birth? Midwifery Today Int Midwife (2003) 0.75